Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma

作     者：Lin-Bo Cai Juan Li Ming-Yao Lai Chang-Guo Shan Zong-De Lian Wei-Ping Hong Jun-Jie Zhen Qing Zhou Li-Chao Wang 

作者机构：Department of Oncology Guangdong 999 Brain Hospital 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2013年第25卷第2期

页      面：206-211页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Bevacizumab recurrent malignant glioma 

摘      要：Objective： We retrospectively studied the efficacy of bevacizumab as salvage therapy for recurrent malignant glioma with a focus on the overall survival （OS）. Methods： Patients who received a therapy other than surgery for recurrent malignant glioma were included. Efficacy was evaluated using MRI. Neurological function was evaluated using the Response Assessment in Neuro-Oncology （RANO）. The survival rate was calculated using the Kaplan-Meier method. Results： Fifty-one patients with recurrent glioma （31 grade Ⅲ, 20 grade Ⅳ） were included. Among them, 22 subjects （43.1%） received bevacizumab. The median OS was 10.2 months （range, 1 to 27 months）. Patients receiving bevacizumab had comparable OS （a median of 9.9 vs. 10.0 months） and similar 6-month survival rate （43% vs. 34%） to those who did not receive bevacizumab. A subgroup analysis failed to notice any significant difference in grade Ⅲ glioma patients receiving bevacizumab vs. those who did not. The median survival was significantly longer at 8.9 months （range, 4 to 13 months） in grade Ⅳ glioma patients receiving bevacizumab than in those who did not （5.6 months, range, 2 to 7 months, P=0.042）. The 6-month survival rate was higher （83 %） in those who received bevacizumab than in those who did not （47 %, P=0.046）. No grade 3/4 adverse events were observed in any patient. Conclusions： Bevacizumab, as a rescue therapy, provides a survival benefit for recurrent grade IV glioma.